Azienda Ospedaliera Sant Anna E San Sebastiano Di Caserta — Clinical Trial Site

40 Registered trials

19 Currently recruiting

Organisation

Azienda Ospedaliera Sant Anna E San Sebastiano Di Caserta

Location

Caserta, Italy

Identifier

ORG-100045836

Address

Via Ferdinando Palasciano Snc, 81100, Italy

Departments

#1611: UOC Cardiologia Clinica e Direzione Universitara UTIC
#2824: UOC Cardiologia Clinica a Direzione Universitaria e UTIC
#3610:US Reumatologia_Medina Interna
2402: UOC Cardiologia Clinica a Direzione Universitaria e UTIC
2806:UOSD Reumatologia
3610; UOS Reumatologia UOC Medicina Interna
Cardiologia
Cardiology
Cardiology Department
Cardiovascular
Cardiovascular Department
Dipartimento Cardio-Vascolare
Medical Oncology
Medical Oncology Unit
N/A
Oncoematologia
Oncohematology
Oncologia
Oncologia Medica
Oncologia Medica e Direzione Universitaria
Oncology
OU Nephrology and Dialysis
Reparto di Cardiologia a Direzione Universitaria - Università della Campania “Luigi Vanvitelli”
U.O. Cardiologia Clinica a Direzione Universitaria e UTIC
U.O.C. Cardiologia
U.O.C. di Cardiologia Clinica a Direzione Universitaria
U.O.C. Oncologia Medica a Direzione Universitaria
Unita Operativa Cardiologia Clinica
UOC Cardiologia a Direzione Universitaria
UOC Cardiologia Clinica a Direzione Universitaria e UTIC
UOC Clinical Cardiology
UOC Oncologia Medica
UOC Oncologia Medica a Direzione Universitaria

Clinical trials at this site (40)

Search interface

A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovasc… Unknown

2022-502779-40-99 Primary prevention of atherosclerotic cardiovascular di 5
OCEAN(a)-PreEvent - Olpasiran trials of Cardiovascular Events And LipoproteiN(a) reduction to Prevent first major cardiovascular Events Pending

2025-520554-11-00 Cardiovascular Disease 5
Impact of GLP1-RAs on inflammation and endothelial biomarkerS in Type 2 diABetes meLlitus patiEnts: STABLE-GLP1 trial. Pending

2025-520802-37-00 Type 2 diabetes mellitus 6
Prevention of Ribociclib-related hepatotoxicity in breast cancer patients: a phase II, multicentre, open label, single arm trial of Silimari… Pending

2025-521651-22-00 hormone receptor positive, HER2-negative breast cancer 4
Obicetrapib Versus Bempedoic Acid to Treat Dyslipidemia in Patients at High to Very High Cardiovascular Risk Recruiting

2025-524265-24-00 Dyslipidemia at High to Very High Cardiovascular Risk 5 2026-05-21
NoLEEta - Phase III non-inferiority trial of chemotherapy de-escalation in hormone receptorpositive, Her2-negative, intermediate-risk early … Recruiting

2025-520979-13-00 Patients with HR+ HER2- early breast cancer at intermed 5 2025-12-18
Combined Dose-Finding and CV Outcomes Study with CSL300 (Clazakizumab) in Adult Subjects with ESKD Undergoing Dialysis (POSIBIL6ESKD). Recruiting

2022-500273-14-00 Atherosclerotic cardiovascular disease in patients with 10 2023-07-17
ROMANCE Recruiting

2025-521319-38-00 metastatic colorectal cancer 4 2026-03-11
Lp(a) lowering study of pelacarsen (TQJ230) with background inclisiran in participants with elevated Lp(a) and established ASCVD Recruiting

2024-516356-18-00 Atherosclerotic cardiovascular disease (ASCVD) 5 2026-02-17
A Study to Learn About the Study Medicine Called PF-08046054/SGNPDL1V Versus Docetaxel in Adult Participants with Previously-treated Program… Recruiting

2025-521281-97-00 Non-Small Cell Lung Cancer (NSCLC) 5 2025-12-02
FORTIFY – Focused Orticumab Research for Treating inflammation in Coronary Arteries Recruiting

2025-520464-17-00 Atherosclerotic Cardiovascular disease 4 2025-10-21
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants with Atherosclerotic Cardiovascular Disease and … Recruiting

2024-516652-18-00 Atherosclerotic cardiovascular disease (ASCVD) and obes 5 2025-10-10
A Trial to Test How AZD0780 Affects Serious Heart, Stroke, or Vascular Problems in Patients with Heart, Stroke or Vascular Disease or at Hig… Recruiting

2025-520519-14-00 Atherosclerotic Cardiovascular Disease 5 2025-09-03
A Study to Assess safety and Effectiveness of the Inavolisib Plus a CDK4/6 Inhibitor and Letrozole Versus Placebo Plus a CDK4/6 Inhibitor an… Recruiting

2024-516162-11-00 Endocrine-Sensitive phosphatidylinositol 3-kinase (PIK3 5 2025-07-14
A Randomized, Double-blinded, Multicenter, Phase Ⅲ Clinical Study of HLX22 (Recombinant Humanized Anti-HER2 Monoclonal Antibody Injection) i… Recruiting

2024-516633-12-00 Locally advanced/ metastatic gastroesophageal junction 5 2025-06-30
Randomized phase 2 study of Valproic acid combinEd with rechallenge anti-EGFR based regimen regimens in pretreated patients with RAS/BRAF wi… Recruiting

2024-514420-16-00 RAS/BRAF wild-type metastatic colorectal cancer 4 2024-12-18
A randomized double-blind, placebo-controlled, multicenter trial assessing the impact of lipoprotein(a) lowering with pelacarsen (TQJ230) on… Recruiting

2022-502135-19-00 Calcific Aortic Valve Stenosis 4 2024-07-18
Randomized phase 3 study of intermittent or continuous Panitumumab plus FOLFIRI for first-line treatment of patients with unresectable left … Recruiting

2023-509551-14-00 Unresectable left sided RAS/B-RAF wild-type metastatic 5 2024-06-12
Phase 3 extension study to evaluate long-term safety of two regimens of ianalumab in participants with systemic lupus erythematosus (SIRIUS-… Recruiting

2023-505929-14-00 Systemic Lupus Erythematosus 5 2024-05-21
A study to Evaluate Efficacy and Safety of Giredestrant Compared with Fulvestrant (plus a CDK4/6 inhibitor), in Participants with ER+ HER2-N… Recruiting

2022-502980-39-00 Estrogen receptor (ER)-positive, HER2-negative advanced 5 2024-01-25
A Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaLuate the effIcacy and safety of abeLacimab… Recruiting

2023-503224-66-00 Atrial Fibrillation 5 2023-10-31
Selatogrel Outcome Study in Suspected Acute Myocardial Infarction Recruiting

2023-505438-85-00 Acute myocardial infarction (AMI) 5 2022-01-12
Palbociclib plus fulvestrant in women with hormone receptor positive and human epidermal growth factor receptor type 2 negative locally adva… Recruiting

2024-513372-18-00 Pre- and post-menopausal women with HR+/HER2- LABC or M 4 2019-10-18
Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a) ( MOVE-Lp(a) ) Ended

2025-521067-13-00 Atherosclerotic Cardiovascular Disease (ASCVD) 5 2026-04-24